newest glp-1 drugs Eli Lilly to seek approval of new weight-loss drug this year A new wave of weight-loss
Description
Orforglipron (Orfoglip), approved in 2025, is an oral GLP-1 agonist for obesity
Chiurazzi M, De Conno B, Di Lauro M, et al
2017;43(Suppl 1):2S202S7
While information on employer plan formularies is not publicly available, these plans may be more likely to cover drugs for weight loss than ACA Marketplace plans given the desire to attract workers, though they may employ similar utilization management strategies.
